MAPT and Alzheimer disease: While drugs targeting AD pathologies, β-amyloid (Aβ) plaques and tau neurofibrillary tangles, are in development and anti-Aβ antibodies have been approved, therapies targeting other mechanisms of AD are desperately needed.